[1]Pauza CD, Liou ML, Lahusen T, et al. Gamma delta T cell therapy for cancer: it is good to be local[J]. Front Immunol, 2018, 9: a1305.doi:10.3389/fimmu.2018.01305 [2]Ng CT, Mendoza JL, Garcia KC, et al. Alpha and beta type 1 interferon signaling: passage for diverse biologic outcomes[J]. Cell, 2016, 164: 349-352. [3]Ives NJ, Suciu S, Eggermont AM, et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis[J]. Eur J Cancer, 2017, 82: 171-183. [4]刘洁.重组人干扰素α1b治疗小儿腺病毒肺炎疗效分析[J].云南医药,2015,36:435-437. [5]Shi WY, Cao C, Liu L. Interferon alpha induces the apoptosis of cervical cancer HeLa cells by activating both the intrinsic mitochondrial pathway and endoplasmic reticulum stress-induced pathway[J]. Int J Mol Sci, 2016,17:1832-1845. [6]Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegy-lated-interferon-alpha therapy of chronic hepatitis B[J]. J Hepatol, 2013,58:225-233. [7]Silva-Santos B, Mensurado S, Coffelt SB. Gammadelta T cells: pleiotropic immune effectors with therapeutic poten-tial in cancer[J]. Nat Rev Cancer, 2019, 19: 392-404. [8]Simoes AE, Lorenzo BD, Silva-Santos B. Molecular determinants of target cell recognition by human gammadelta T Cells[J]. Front Immunol, 2018, 9: 929-936. [9]Dai YM, Liu HY, Liu YF, et al. EBV transformation induces overexpression of hMSH2/3/6 on B lymphocytes and enhances gammadelta T-cell-mediated cytotoxicity via TCR and NKG2D[J]. Immunology, 2018,154:673-682. [10]Kong Y, Cao W, Xi XY, et al. The NKG2D ligand ULBP4 binds to TCR gamma9/delta2 and induces cytotoxicity to tumor cells through both TCR gammadelta and NKG2D[J]. Blood, 2009, 114:310-317. [11]Presti EL, Pizzolato G, Corsale AM, et al. Gammadelta T cells and tumor microenvironment: from immunosurveil-lance to tumor evasion[J]. Front Immunol, 2018,9: a1395. doi: 10.3389/fimmu.2018.01395. |